CSL (CSJ) Q4 2026 Earnings Report

The call presented a mix of stabilization and operational progress (strong cash flow, ahead-of-plan transformation savings, Ig momentum in H2, successful new product launches and Seqirus share gains) but was overshadowed by very large impairments, a statutory net loss, and significant, structural headwinds in Vifor (anticipated ~25% revenue decline) plus continued pressure on albumin. While management has a clear remediation plan and delivered early positive operational signs, the scale and persistence of the portfolio and impairment issues materially weaken near-term financial prospects.

CSL guided FY‑27 group revenue to be broadly in line with FY‑26 (FY‑26 revenue $15.8bn, down 1% constant FX) and underlying NPAT to grow roughly 5% at constant currency (excluding restructuring and impairments), while warning of an approximately $50m FX headwind at current rates; division guidance was Behring mid‑single‑digit revenue growth with Ig mid‑ to high‑single‑digit growth and a modest gross‑margin improvement (aiming to recover roughly the ~70bp lost in FY‑26), Seqirus low‑single‑digit growth, and Vifor an ~25% revenue decline (no TAVNEOS sales in FY‑27, Velphoro TDAPA benefit ceasing end‑2026). Management expects FY‑27 incremental transformation savings of ~ $220m (taking annualized savings to ~ $400m and up to $550m in FY‑28) with about half to be reinvested into commercial and R&D, FY‑27 CapEx of ~ $1.0bn ± $100m, a new AUD 1.1bn buyback (after the AUD 1bn completed in FY‑26), maintained FY‑26 dividend (final $1.62, full year $2.92 per share), strong operating cash flow ($3.5bn in FY‑26), and a target net debt/EBITDA range of 1.5–2x (FY‑26 net debt/EBITDA 1.8x).